Proteomic analysis of rat brains following exposure to electroconvulsive therapy

Journal of Korean Medical Science

Volumn 24, Issue 1, 2009, Pages 132-137

  Lee, Cheol Soon ^a   Kang, Kee Ryeon ^a   Lee, Ji Young ^a   Park, Chul Soo ^a   Hahn, Kyu Hee ^a   Sohn, Jin Wook ^a   Kim, Bong Jo ^a  

^a Gyeongsang National University School of Medicine   (South Korea)

Author keywords

Electroconvulsive therapy; Proteomics

Indexed keywords

PROTEOME;

ANIMAL; ARTICLE; BRAIN; ELECTROCONVULSIVE THERAPY; MASS SPECTROMETRY; METABOLISM; METHODOLOGY; PROTEOMICS; RAT; TWO DIMENSIONAL GEL ELECTROPHORESIS; UPREGULATION;

ANIMALS; BRAIN; ELECTROCONVULSIVE THERAPY; ELECTROPHORESIS, GEL, TWO-DIMENSIONAL; PROTEOME; PROTEOMICS; RATS; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION; UP-REGULATION;

EID: 65649103652     PISSN: 10118934     EISSN: 15986357     Source Type: Journal    
DOI: 10.3346/jkms.2009.24.1.132     Document Type: Article

References (24)

1. Shergill SS, Katona CL. Pharmacotherapy of affective disorders. In: Helmchen H, Henn F, Lauter H, Sartorius N, eds. Contemporary Psychiatry. 4th ed. Heidelberg: Springer 2001; 317-36.
2. Rohlff C. Proteomics in molecular medicine: applications in central nervous systems disorders. Electrophoresis 2000; 21: 1227-34.
3. Morrison RS, Kinoshita Y, Johnson MD, Conrads TP. Proteomics in the postgenomic age. Adv Protein Chem 2003; 65: 1-23.
4. Moseley FL, Bicknell KA, Marber MS, Brooks G. The use of proteomics to identify novel therapeutic targets for the treatment of disease. J Pharm Pharmacol 2007; 59: 609-28.
5. Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 1976; 72: 248-54.
6. Gorg A, Weiss W, Dunn MJ. Current two-dimensional electrophoresis technology for proteomics. Proteomics 2004; 4: 3665-85.
7. Hwa JS, Kim HJ, Goo BM, Park HJ, Kim CW, Chung KH, Park HC, Chang SH, Kim YW, Kim DR, Cho GJ, Choi WS, Kang KR. The expression of ketohexokinase is diminished in human clear cell type of renal cell carcinoma. Proteomics 2006; 6: 1077-84.
8. Donato R. S100: a multigenic family of calcium-modulated proteins of the EF-hand type with intracellular and extracellular functional roles. Int J Biochem Cell Biol 2001; 33: 637-68.
9. Rothermundt M, Falkai P, Ponath G, Abel S, Burkle H, Diedrich M, Hetzel G, Peters M, Siegmund A, Pedersen A, Maier W, Schramm J, Suslow T, Ohrmann P, Arolt V. Glial cell dysfunction in schizophrenia indicated by increased S100B in the CSF. Mol Psychiatry 2004; 9: 897-9.
10. Busnello JV, Leke R, Oses JP, Feier G, Bruch R, Quevedo J, Kapczinski F, Souza DO, Cruz Portela LV. Acute and chronic electroconvulsive shock in rats: effects on peripheral markers of neuronal injury and glial activity. Life Sci 2006; 78: 3013-7.
11. Yaffe MB, Rittinger K, Volinia S, Caron PR, Aitken A, Leffers H, Gamblin SJ, Smerdon SJ, Cantley LC. The structural basis for 14-3-3: phosphopeptide binding specificity. Cell 1997; 91: 961-71.
12. Urschel S, Bassermann F, Bai RY, Munch S, Peschel C, Duyster J. Phosphorylation of Grb10 regulates its interaction with 14-3-3. J Biol Chem 2005; 280: 16987-93.
13. Bell R, Munro J, Russ C, Powell JF, Bruinvels A, Kerwin RW, Collier DA. Systematic screening of the 14-3-3 eta (n) chain gene for polymorphic variants and case-control analysis in schizophrenia. Am J Med Genet 2000; 96: 736-43.
14. Vawter MP, Barrett T, Cheadle C, Sokolov BP, Wood WH 3rd, Donovan DM, Webster M, Freed WJ, Becker KG. Application of cDNA microarrays to examine gene expression differences in schizophrenia. Brain Res Bull 2001; 55: 641-50.
15. Wong AH, Macciardi F, Klempan T, Kawczynski W, Barr CL, Lakatoo S, Wong M, Buckle C, Trakalo J, Boffa E, Oak J, Azevedo MH, Dourado A, Coelho I, Macedo A, Vicente A, Valente J, Ferreira CP, Pato MT, Pato CN, Kennedy JL, Van Tol HH. Identification of candidate genes for psychosis in rat models, and possible association between schizophrenia and the 14-3-3eta gene. Mol Psychiatry 2003; 8: 156-66.
16. Middleton FA, Peng L, Lewis DA, Levitt P, Mirnics K. Altered expression of 14-3-3 genes in the prefrontal cortex of subjects with schizophrenia. Neuropsychopharmacology 2005; 30: 974-83.
17. Thomas GM, Cunningham E, Fensome A, Ball A, Totty NF, Truong O, Hsuan JJ, Cockcroft S. An essential role for phosphatidylinositol transfer protein in phospholipase C-mediated inositol lipid signaling. Cell 1993; 74: 919-28.
18. Kauffmann-Zeh A, Thomas GM, Ball A, Prosser S, Cunningham E, Cockcroft S, Hsuan JJ. Requirement for phosphatidylinositol transfer protein in epidermal growth factor signaling. Science 1995; 268: 1188-90.
19. Baraban JM. Toward a crystal-clear view of lithium's site of action. Proc Natl Acad Sci, USA 1994; 91: 5738-9.
20. Pollack SJ, Atack JR, Knowles MR, McAllister G, Ragan CI, Baker R, Fletcher SR, Iversen LL, Broughton HB. Mechanism of inositol monophosphatase, the putative target of lithium therapy. Proc Natl Acad Sci, USA 1994; 91: 5766-70.
21. Manji HK, Chen G, Hsiao JK, Risby ED, Masana MI, Potter WZ. Regulation of signal transduction pathways by mood-stabilizing agents: implications for the delayed onset of therapeutic efficacy. J Clin Psychiatry 1996; 57 (Suppl 13): 34-46.
22. Giardina T, Biagini A, Massey-Harroche D, Puigserver A. Distribution and subcellular localization of acylpeptide hydrolase and acylase I along the hog gastro-intestinal tract. Biochimie 1999; 81: 1049-55.
23. Lindner H, Hopfner S, Tafler-Naumann M, Miko M, Konrad L, Rohm KH. The distribution of aminoacylase I among mammalian species and localization of the enzyme in porcine kidney. Biochimie 2000; 82: 129-37.
24. Cook RM, Franklin WA, Moore MD, Johnson BE, Miller YE. Mutational inactivation of aminoacylase-I in a small cell lung cancer cell line. Genes Chromosomes Cancer 1998; 21: 320-5.